BULLISHWHALES
BullishWhales · Analysts · Analyst Profile
BW Score Rank#264 of 347

Sumant Kulkarni

Canaccord Genuity · Equity Research Analyst
ProvisionalRating since 2022No new ratings since May 2025

Analyst rating accuracy & track record

Sumant Kulkarni is an equity research analyst at Canaccord Genuity. Bullish Whales has scored 20 of their stock calls across 8 companies. Their picks beat their sector 37% of the time over the next 12 months, and their price targets were reached 24% of the time within a year.

Win % vs sector
37%
PT Hit % (12mo)
24%
Avg sector-excess
−15.2%
Scored calls
20
Tickers
8
Tier
Provisional

Track record

Bullish Whales has scored 20 of Sumant Kulkarni's stock calls across 8 companies, dating back to 2022. Their rated stocks beat their own sector 37% of the time over the next 12 months. On a typical call, a Kulkarni pick returned −15.2% more than its sector over the following year.

Of the scored calls, 20 were bullish (Buy). Most of their coverage sits in Healthcare. Every number on this page is an estimate from our own data. It is for education only and is not investment advice.

Coverage & ratings

Ratings & price targets

StockRatingPrice targetRated12-mo vs sectorPT hit
ANVSAnnovis Bio Inc
Buy$17.00May 2025+4.1%Miss
VYGRVoyager Therapeutics Inc
Buy$12.00Mar 2025+9.2%Miss
ZVRAZevra Therapeutics Inc.
Buy$25.00Mar 2025+14.9%Miss
CMPSCompass Pathways Plc
Buy$15.00Feb 2025+83.4%Miss
BTAIBioXcel Therapeutics Inc
Buy$5.00Jan 2025−92.1%Miss
ATAIATAI Life Sciences BV
Buy$11.00Nov 2024+117.2%Miss
VYGRVoyager Therapeutics Inc
Buy$14.00Nov 2024−39.3%Miss
ZVRAZevra Therapeutics Inc.
Buy$23.00Nov 2024−5.9%Miss
ZVRAZevra Therapeutics Inc.
Buy$22.00Sep 2024+9.3%Miss
BTAIBioXcel Therapeutics Inc
Buy$7.00Aug 2024−50.9%Miss
BTAIBioXcel Therapeutics Inc
Buy$7.00Jun 2024−84.8%Miss
ANVSAnnovis Bio Inc
Buy$26.00Apr 2024−77.1%Miss
BTAIBioXcel Therapeutics Inc
Buy$7.00Mar 2024−96.3%Miss
TVRDTvardi Therapeutics, Inc.
Buy$10.00Mar 2024−65.0%Miss
ANVSAnnovis Bio Inc
Buy$36.00Dec 2023−73.6%Miss
VYGRVoyager Therapeutics Inc
Buy$14.00May 2023−24.6%Hit
STOKStoke Therapeutics Inc
Buy$24.00Apr 2023+26.3%Miss
TVRDTvardi Therapeutics, Inc.
Buy$25.00Mar 2023−102.1%Miss
ZVRAZevra Therapeutics Inc.
Buy$20.00Sep 2022−26.5%Miss
TVRDTvardi Therapeutics, Inc.
Buy$29.00Mar 2022−46.5%Miss
Go to

Sumant Kulkarni: analyst track record FAQ

Is Sumant Kulkarni a good stock analyst?

Yes, by track record. Sumant Kulkarni ranks number 264 of 347 of the analysts Bullish Whales scores, with a BW Score of 4 out of 100. Past results do not guarantee future ones.

What is Sumant Kulkarni's win rate?

Sumant Kulkarni's win rate is 37%. Across 20 scored calls, their rated stocks beat their sector 37% of the time over the next 12 months. On a typical call they returned −15.2% more than the sector.

What stocks and sectors does Sumant Kulkarni cover?

Sumant Kulkarni covers 8 companies, with the most coverage in Healthcare. See the ratings table above for every scored call and its outcome.

Are Sumant Kulkarni's price targets accurate?

Sumant Kulkarni's price targets are reached within 12 months 24% of the time. The base rate across all analysts Bullish Whales tracks is about 43 percent.

How accurate are Wall Street analyst price targets?

Most analyst price targets are not reached on schedule. Across every target Bullish Whales scores, the stock reaches the target within 12 months only about 43 percent of the time, which is why it helps to compare hit rates analyst by analyst.

Should I follow Sumant Kulkarni's stock ratings?

Their track record is strong, but no analyst is right every time. Follow the long-term track record rather than any single rating, size your positions to your own risk, and treat this as research, not investment advice.

How does Bullish Whales score analyst accuracy?

Bullish Whales scores every rating on real prices. We enter at the closing price on or after the call date, with no look-ahead, then measure the 12-month return above the stock's sector ETF and check whether the price target was reached. Scores are pulled toward the population average and corrected for testing thousands of analysts at once, so they reflect repeatable skill rather than luck.

How does Sumant Kulkarni rank among Wall Street analysts?

Sumant Kulkarni ranks number 264 of 347 by BW Score. We rank analysts by their realized 12-month sector-excess return and require a minimum number of calls so a few lucky picks cannot reach the top.

Browse the full analyst leaderboardHow analyst accuracy is scored

Every score, Win %, PT Hit % and rank is an estimate Bullish Whales calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.

v1.0.30